Metrics Expands Analytical Capabilities
Metrics Contract Services Expands Analytical Lab Capabilities With Additional UPLC Equipment
The company’s investment in leading liquid chromatography technologies will provide additional capability in services clients are seeking.
6 August 2015: Metrics Contract Services (Metrics) is expanding its analytical lab capabilities by adding two new UPLC systems.
Metrics has acquired two new Waters ACQUITY Ultra Performance Liquid Chromatography™ H-class (UPLC) systems. These additional UPLC systems will help the company’s chemists produce better resolution liquid-chromatography separations in shorter analysis times, thus improving characterization of complex samples.
“Our clients have been requesting our help with exactly these types of analytical projects, so it’s exciting to expand our capabilities in support of our customers’ programs,” said Jennifer Alligood, associate director of analytical services.
This equipment acquisition is the latest in a series of investments Metrics has been making in its physical facilities and equipment. Most recently, the company added a Thermo Scientific™ iCAP™ Q ICP-MS mass spectrometer and a Milestone UltraWAVE Single Reaction Chamber digestion vessel.
“Metrics’ ongoing investment in leading-edge laboratory technologies reflects our commitment to providing clients with scientific excellence — in terms of providing quality data and fast turnaround times, as well as thoughtful interpretation of what those results mean for them,” Alligood added.
Metrics has long appreciated the importance of analytical support within the context of pharmaceutical development and manufacturing. Today, Metrics has more than 90 analytical chemists on staff — which represents an industry-leading four analytical chemists for every one of the company’s formulation experts. Metrics analytical chemists work within a current Good Manufacturing Practices-complaint facility on a wide range of oral dosage forms, including potent, cytotoxic, light-sensitive, temperature-sensitive, DEA-regulated, and other challenging molecules.
About Metrics Contract Services
Metrics Inc. is a full-service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for oral dosage forms.
Our company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial scale manufacturing.
Our technical capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence, for which we offer an impressive proprietary portfolio of advanced delivery methods. Located in Greenville, N.C., Metrics is a proud member of the Mayne Pharma family.
About Mayne Pharma
Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company develops and manufactures branded and generic products globally – either directly or through distribution partners – while applying its drug-delivery expertise for contract development and manufacturing services.
Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world. Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds.